<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636868</url>
  </required_header>
  <id_info>
    <org_study_id>03-CL-1202</org_study_id>
    <nct_id>NCT02636868</nct_id>
  </id_info>
  <brief_title>The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age</brief_title>
  <official_title>A Multinational, Multicenter, Masked, Randomized, Controlled Study to Assess The Safety and Efficacy of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age With Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Windtree Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Windtree Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and efficacy of lucinactant for&#xD;
      inhalation administered as an aerosolized dose in two doses to preterm neonates 26 - 32 weeks&#xD;
      gestational age who are receiving nasal continuous positive airway pressure (nCPAP) for&#xD;
      Respiratory Distress Syndrome (RDS) compared to neonates receiving nCPAP alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of lucinactant for&#xD;
      inhalation in preterm neonates 26 to 32 completed weeks post-menstrual age (PMA). Efficacy&#xD;
      and safety are based on clinical evaluations. The endpoints specified are similar to those in&#xD;
      Protocols 03-CL-1201 and 03-CL-1401 to allow for potential comparison and pooling of results.&#xD;
&#xD;
      The objective of this study is to evaluate the safety and efficacy of lucinactant for&#xD;
      inhalation in conjunction with nCPAP, compared to nCPAP alone, in preterm neonates with RDS,&#xD;
      as assessed by the time to and incidence of respiratory failure and/or death due to RDS over&#xD;
      the first 72 hours of life, the incidence of bronchopulmonary dysplasia (BPD) at 36 weeks&#xD;
      PMA, and change in physiologic parameters (FiO2 and PCO2) over the first 72 hours of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Actual">August 6, 2019</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Respiratory Failure or Death Due to Respiratory Distress Syndrome (RDS)</measure>
    <time_frame>72 hours</time_frame>
    <description>Number of participants who had respiratory failure due to RDS or death due to RDS; known as nasal continuous positive airway pressure (nCPAP) failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Respiratory Failure or Death Due to RDS</measure>
    <time_frame>72 hours</time_frame>
    <description>Incidence of Respiratory Failure or Death Due to RDS by Intubation or Failure Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to nCPAP Failure</measure>
    <time_frame>72 hours</time_frame>
    <description>Time from birth to nCPAP Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Respiratory Failure or Death Due to RDS With Poisson Distribution Modeling</measure>
    <time_frame>72 hours</time_frame>
    <description>The measure tests the differences between treatments on respiratory failure or death due to RDS using Poisson distribution modeling, which accounts for the time over which the event could have occurred.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Respiratory Failure or Death Due to RDS</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of Respiratory Failure or Death due to RDS by Intubation or Failure Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bronchopulmonary Dysplasia (BPD)</measure>
    <time_frame>36 weeks post-menstrual age (PMA)</time_frame>
    <description>Summarizes the number of participants with BPD or alive without BPD</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">221</enrollment>
  <condition>Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Aerosolized lucinactant (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosolized lucinactant (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nasal CPAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nCPAP alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucinactant delivered via investigational delivery device</intervention_name>
    <description>Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)</description>
    <arm_group_label>Aerosolized lucinactant (high dose)</arm_group_label>
    <arm_group_label>Aerosolized lucinactant (low dose)</arm_group_label>
    <other_name>AEROSURF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nCPAP</intervention_name>
    <description>Nasal CPAP</description>
    <arm_group_label>Aerosolized lucinactant (high dose)</arm_group_label>
    <arm_group_label>Aerosolized lucinactant (low dose)</arm_group_label>
    <arm_group_label>nasal CPAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form (ICF) from legally authorized representative&#xD;
&#xD;
          2. 26 0/7 to 32 6/7 completed weeks gestation PMA&#xD;
&#xD;
          3. Successful implementation of non-invasive support or ventilation within 90 minutes&#xD;
             after birth&#xD;
&#xD;
          4. Spontaneous breathing&#xD;
&#xD;
          5. Chest radiograph consistent with RDS&#xD;
&#xD;
          6. Within the first 20 hours after birth requires an nCPAP of 5 to 7 centimeters water&#xD;
             (cmH2O) with a fraction of inspired oxygen (FiO2) of ≥ 0.25 (&gt;0.21 for neonates 26-28&#xD;
             weeks PMA) to 0.40 that is clinically indicated for at least 30 minutes to maintain&#xD;
             oxygen by pulse oximetry (SpO2) of 90% to 95%. Transient (&lt;10 minutes) FiO2 excursions&#xD;
             outside this range do not reset the 30-minute requirement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A heart rate that cannot be stabilized above 100 beats per minute (bpm) within 5&#xD;
             minutes of birth&#xD;
&#xD;
          2. Recurrent episodes of apnea requiring positive pressure ventilation (PPV) administered&#xD;
             manually or mechanically through any patient interface&#xD;
&#xD;
          3. A 5 minute Apgar score &lt; 5&#xD;
&#xD;
          4. Major congenital malformation(s) or craniofacial abnormalities that preclude the use&#xD;
             of nCPAP, diagnosed antenatally or immediately after birth&#xD;
&#xD;
          5. Clinically significant diseases or conditions other than RDS which could potentially&#xD;
             interfere with cardiopulmonary function (e.g. congenital heart disease, hydrops&#xD;
             fetalis or congenital infection)&#xD;
&#xD;
          6. A known or suspected chromosomal abnormality or syndrome&#xD;
&#xD;
          7. Premature rupture of membranes (PROM) &gt; 3 weeks&#xD;
&#xD;
          8. Hemodynamic instability requiring vasopressors or steroids for hemodynamic support&#xD;
             and/or presumed clinical sepsis&#xD;
&#xD;
          9. A need for intubation and/or mechanical ventilation at any time before enrollment into&#xD;
             the study&#xD;
&#xD;
         10. The administration (or plan for administration) of any the following:&#xD;
&#xD;
               -  Another investigational agent or investigational medical device&#xD;
&#xD;
               -  Any other surfactant agent&#xD;
&#xD;
               -  Systemic corticosteroids (other than antenatal steroids already received)&#xD;
&#xD;
         11. Presence of air leak (pneumothorax, pneumomediastinum, pneumopericardium, subcutaneous&#xD;
             emphysema, or definite evidence of pulmonary interstitial emphysema (PIE)) on the&#xD;
             baseline chest radiograph&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>26 Weeks</minimum_age>
    <maximum_age>32 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Simonson, MD</last_name>
    <role>Study Director</role>
    <affiliation>Windtree Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Arkansas Medical Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Mary Birch Hospital for Women and Newborns</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health System</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Holtz Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morgan Stanley Childrens Hospital of New York Presbyterian (CHONY)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brody School of Medicine at ECU</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hanover Regional Medical Center</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University (Rainbow Babies Hosp.)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women and Infants Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook Children's Hospital</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Health Harris Methodist Hospital</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Children's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sainte Justine Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr Sotero Del Rio</name>
      <address>
        <city>Santiago</city>
        <state>Region-MetropolitanadeSantiago</state>
        <zip>8207257</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Regional de Concepción Dr Guillermo Grant Benavente</name>
      <address>
        <city>Concepción</city>
        <zip>4070038</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Jose</name>
      <address>
        <city>Santiago</city>
        <zip>3330</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Alamena de Santiago</name>
      <address>
        <city>Santiago</city>
        <zip>7650568</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santiago Oriente Dr Luis Tisné Brousse</name>
      <address>
        <city>Santiago</city>
        <zip>7980378</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico de la Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <zip>8330024</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Dios</name>
      <address>
        <city>Santiago</city>
        <zip>8350488</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Hospitalaria San Vicente de Paul</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050010</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Medellin</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050015</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle Del Lili</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760032</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>1082</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csolnoky Ferenc Korhaz</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Kozpont</name>
      <address>
        <city>Debrecen</city>
        <zip>H-4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Okato</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz</name>
      <address>
        <city>Nyiregyhaza</city>
        <zip>H-4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <zip>T12 YN60</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Western Regional Hospital Limerick</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>S.U. nr2im. Dr. Jana Biziela Oddzial Kliniczny N. W. Z. Intensywna Terapia Noworodka wraz z Wgjazdowy m Zespolem N</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorksie</state>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowja Matki Polki Klinika Neonatologii</name>
      <address>
        <city>Lodz</city>
        <state>Lodzkie</state>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SP ZOZ Szpital Uniwersytecki w Krakowie, Oddzial Neonatologii</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im. Ks, Anny Mazowieckiej Klinika Neonatologii</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>00-315</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-402</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Spegialistycszny nr 2 w Bytomia Oddzial Noworodkow Blok V</name>
      <address>
        <city>Bytom</city>
        <state>Slaskie</state>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Specjalistczny Zaklad Opieki Zdrowotnej Zdroje</name>
      <address>
        <city>Szczecin</city>
        <state>West Pomerania</state>
        <zip>70-780</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ginekologiczno-Polozniczy Szpital Klinicznym UM im. Karola Marcinkowskiego w Poznan i u Katedra Neonatologii</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>60-535</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>December 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <results_first_submitted>February 5, 2021</results_first_submitted>
  <results_first_submitted_qc>March 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2021</results_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02636868/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02636868/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 25, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02636868/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Aerosolized Lucinactant (40 mg TPL/kg)</title>
          <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
        </group>
        <group group_id="P2">
          <title>Aerosolized Lucinactant (80 mg TPL/kg)</title>
          <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
        </group>
        <group group_id="P3">
          <title>nCPAP Only</title>
          <description>nCPAP alone&#xD;
nCPAP: Nasal CPAP</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Randomized Participants</population>
      <group_list>
        <group group_id="B1">
          <title>Aerosolized Lucinactant (40 mg TPL/kg)</title>
          <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
        </group>
        <group group_id="B2">
          <title>Aerosolized Lucinactant (80 mg TPL/kg)</title>
          <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
        </group>
        <group group_id="B3">
          <title>nCPAP Only</title>
          <description>nCPAP alone&#xD;
nCPAP: Nasal CPAP</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="72"/>
            <count group_id="B4" value="221"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>weeks post menstrual age</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Gestational Age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.8" spread="1.24"/>
                    <measurement group_id="B2" value="30.7" spread="1.17"/>
                    <measurement group_id="B3" value="30.7" spread="1.17"/>
                    <measurement group_id="B4" value="30.7" spread="1.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="160"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth Weight</title>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1557.0" spread="342.38"/>
                    <measurement group_id="B2" value="1505.8" spread="378.5"/>
                    <measurement group_id="B3" value="1446.4" spread="359.13"/>
                    <measurement group_id="B4" value="1503.4" spread="361.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ruptured Membranes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Spontaneous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Artificial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chorioamnionitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Steroid Use, Maternal</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Used Steroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Steroids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mode of Delivery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Vaginal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cesarean Section</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Single Birth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Birth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Appearance, Pulse, Grimace, Activity, and Respiration (Apgar) Score at One Minute</title>
          <description>In the test, five things are used to check a baby's health at 1 minutes after birth. Each is scored on a scale of 0 to 2, with 2 being the best score:&#xD;
Appearance (skin color) Pulse (heart rate) Grimace response (reflexes) Activity (muscle tone) Respiration (breathing rate and effort) The individual scores are summed to determine the total score.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.7" spread="1.74"/>
                    <measurement group_id="B2" value="6.5" spread="1.71"/>
                    <measurement group_id="B3" value="6.8" spread="1.61"/>
                    <measurement group_id="B4" value="6.6" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Apgar Score at Five Minutes</title>
          <description>In the test, five things are used to check a baby's health at 5 minutes after birth. Each is scored on a scale of 0 to 2, with 2 being the best score:&#xD;
Appearance (skin color) Pulse (heart rate) Grimace response (reflexes) Activity (muscle tone) Respiration (breathing rate and effort) The individual scores are summed to determine the total score.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1" spread="0.90"/>
                    <measurement group_id="B2" value="8.0" spread="1.02"/>
                    <measurement group_id="B3" value="8.1" spread="1.00"/>
                    <measurement group_id="B4" value="8.1" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Congenital Anomaly</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Respiratory Failure or Death Due to Respiratory Distress Syndrome (RDS)</title>
        <description>Number of participants who had respiratory failure due to RDS or death due to RDS; known as nasal continuous positive airway pressure (nCPAP) failure</description>
        <time_frame>72 hours</time_frame>
        <population>Modified Intent-to-Treat; randomized subjects who received study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Aerosolized Lucinactant (40 mg TPL/kg)</title>
            <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
          </group>
          <group group_id="O2">
            <title>Aerosolized Lucinactant (80 mg TPL/kg)</title>
            <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
          </group>
          <group group_id="O3">
            <title>nCPAP Only</title>
            <description>nCPAP alone&#xD;
nCPAP: Nasal CPAP</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Respiratory Failure or Death Due to Respiratory Distress Syndrome (RDS)</title>
          <description>Number of participants who had respiratory failure due to RDS or death due to RDS; known as nasal continuous positive airway pressure (nCPAP) failure</description>
          <population>Modified Intent-to-Treat; randomized subjects who received study treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference across treatment groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.363</p_value>
            <p_value_desc>a priori threshold of statistical significance set at 0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Pooled site, treatment, gender, birth weight, and baseline fraction of inspired oxygen (FiO₂) in model</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between treatments</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.360</p_value>
            <p_value_desc>a priori threshold of statistical significance set at 0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Pooled site, treatment, gender, birth weight, and baseline FiO₂ in model</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between treatments</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.461</p_value>
            <p_value_desc>a priori threshold of statistical significance set at 0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Pooled site, treatment, gender, birth weight, and baseline FiO₂ in model</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Respiratory Failure or Death Due to RDS</title>
        <description>Incidence of Respiratory Failure or Death Due to RDS by Intubation or Failure Criteria</description>
        <time_frame>72 hours</time_frame>
        <population>Modified Intent-to-Treat Population without Treatment Interruptions</population>
        <group_list>
          <group group_id="O1">
            <title>Aerosolized Lucinactant (40 mg TPL/kg)</title>
            <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
          </group>
          <group group_id="O2">
            <title>Aerosolized Lucinactant (80 mg TPL/kg)</title>
            <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
          </group>
          <group group_id="O3">
            <title>nCPAP Only</title>
            <description>nCPAP alone&#xD;
nCPAP: Nasal CPAP</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Respiratory Failure or Death Due to RDS</title>
          <description>Incidence of Respiratory Failure or Death Due to RDS by Intubation or Failure Criteria</description>
          <population>Modified Intent-to-Treat Population without Treatment Interruptions</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="44"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference across treatment groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.401</p_value>
            <p_value_desc>a priori threshold of statistical significance set at 0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Pooled site, treatment, gender, birth weight, and baseline FiO₂ in model</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference across treatment groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.372</p_value>
            <p_value_desc>a priori threshold of statistical significance set at 0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Pooled site, treatment, gender, birth weight, and baseline FiO₂ in model</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is no difference across treatment groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.648</p_value>
            <p_value_desc>a priori threshold of statistical significance set at 0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Pooled site, treatment, gender, birth weight, and baseline FiO₂ in model</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to nCPAP Failure</title>
        <description>Time from birth to nCPAP Failure</description>
        <time_frame>72 hours</time_frame>
        <population>Modified Intent-to-Treat; randomized participants who received study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Aerosolized Lucinactant (40 mg TPL/kg)</title>
            <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
          </group>
          <group group_id="O2">
            <title>Aerosolized Lucinactant (80 mg TPL/kg)</title>
            <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
          </group>
          <group group_id="O3">
            <title>nCPAP Only</title>
            <description>nCPAP alone&#xD;
nCPAP: Nasal CPAP</description>
          </group>
        </group_list>
        <measure>
          <title>Time to nCPAP Failure</title>
          <description>Time from birth to nCPAP Failure</description>
          <population>Modified Intent-to-Treat; randomized participants who received study treatment</population>
          <units>hours</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" spread="2.06"/>
                    <measurement group_id="O2" value="44.8" spread="2.69"/>
                    <measurement group_id="O3" value="40.7" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference across treatments</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.996</p_value>
            <p_value_desc>a priori threshold of statistical significance set at 0.05</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between treatments</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.951</p_value>
            <p_value_desc>a priori threshold of statistical significance set at 0.05</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between treatments</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.995</p_value>
            <p_value_desc>a priori threshold of statistical significance set at 0.05</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Respiratory Failure or Death Due to RDS With Poisson Distribution Modeling</title>
        <description>The measure tests the differences between treatments on respiratory failure or death due to RDS using Poisson distribution modeling, which accounts for the time over which the event could have occurred.</description>
        <time_frame>72 hours</time_frame>
        <population>Modified Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aerosolized Lucinactant (40 mg TPL/kg)</title>
            <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
          </group>
          <group group_id="O2">
            <title>Aerosolized Lucinactant (80 mg TPL/kg)</title>
            <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
          </group>
          <group group_id="O3">
            <title>nCPAP Only</title>
            <description>nCPAP alone&#xD;
nCPAP: Nasal CPAP</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Respiratory Failure or Death Due to RDS With Poisson Distribution Modeling</title>
          <description>The measure tests the differences between treatments on respiratory failure or death due to RDS using Poisson distribution modeling, which accounts for the time over which the event could have occurred.</description>
          <population>Modified Intent-to-Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between treatment groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.312</p_value>
            <p_value_desc>A priori threshold of statistical significance set at 0.10</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Generalized linear model using Poisson distribution with pooled site, treatment, gender, birth weight, and baseline FiO₂ in model</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between treatment groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.094</p_value>
            <p_value_desc>A priori threshold of statistical significance set at 0.10</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Generalized linear model using Poisson distribution with pooled site, treatment, gender, birth weight, and baseline FiO₂ in model</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between treatment groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.414</p_value>
            <p_value_desc>A priori threshold of statistical significance set at 0.10</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>Generalized linear model using Poisson distribution with pooled site, treatment, gender, birth weight, and baseline FiO₂ in model.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Respiratory Failure or Death Due to RDS</title>
        <description>Incidence of Respiratory Failure or Death due to RDS by Intubation or Failure Criteria</description>
        <time_frame>28 days</time_frame>
        <population>Modified Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aerosolized Lucinactant (40 mg TPL/kg)</title>
            <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
          </group>
          <group group_id="O2">
            <title>Aerosolized Lucinactant (80 mg TPL/kg)</title>
            <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
          </group>
          <group group_id="O3">
            <title>nCPAP Only</title>
            <description>nCPAP alone&#xD;
nCPAP: Nasal CPAP</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Respiratory Failure or Death Due to RDS</title>
          <description>Incidence of Respiratory Failure or Death due to RDS by Intubation or Failure Criteria</description>
          <population>Modified Intent-to-Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between treatment groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.099</p_value>
            <p_value_desc>A priori statistical significance of 0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Pooled site, treatment, gender, birth weight, and baseline fraction of inspired oxygen (FiO2) in model</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between treatments</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.090</p_value>
            <p_value_desc>A priori statistical significance of 0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Pooled site, treatment, gender, birth weight, and baseline FiO2 in model</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between treatment groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.461</p_value>
            <p_value_desc>A priori statistical significance of 0.05</p_value_desc>
            <method>Regression, Logistic</method>
            <method_desc>Pooled site, treatment, gender, birth weight, and baseline FiO2 in model</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bronchopulmonary Dysplasia (BPD)</title>
        <description>Summarizes the number of participants with BPD or alive without BPD</description>
        <time_frame>36 weeks post-menstrual age (PMA)</time_frame>
        <population>Modified Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Aerosolized Lucinactant (40 mg TPL/kg)</title>
            <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
          </group>
          <group group_id="O2">
            <title>Aerosolized Lucinactant (80 mg TPL/kg)</title>
            <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
          </group>
          <group group_id="O3">
            <title>nCPAP Only</title>
            <description>nCPAP alone&#xD;
nCPAP: Nasal CPAP</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bronchopulmonary Dysplasia (BPD)</title>
          <description>Summarizes the number of participants with BPD or alive without BPD</description>
          <population>Modified Intent-to-Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alive without BPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no treatment between treatments</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.534</p_value>
            <p_value_desc>A priori threshold for statistical significance set at 0.05</p_value_desc>
            <method>ANOVA</method>
            <method_desc>treatment and pooled site in model</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between treatment groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.480</p_value>
            <p_value_desc>A priori threshold for statistical significance set at 0.05</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and pooled site in model</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis of no difference between treatment groups</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.313</p_value>
            <p_value_desc>A priori threshold for statistical significance set at 0.05</p_value_desc>
            <method>ANOVA</method>
            <method_desc>Treatment and pooled site in model</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Enrollment to 36 weeks post-menstrual age</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aerosolized Lucinactant (40 mg TPL/kg)</title>
          <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
        </group>
        <group group_id="E2">
          <title>Aerosolized Lucinactant (80 mg TPL/kg)</title>
          <description>Lucinactant for inhalation with nCPAP; up to 2 repeat doses will be allowed if repeat dosing criteria are met.&#xD;
Lucinactant delivered via investigational delivery device: Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)&#xD;
nCPAP: Nasal CPAP</description>
        </group>
        <group group_id="E3">
          <title>nCPAP Only</title>
          <description>nCPAP alone&#xD;
nCPAP: Nasal CPAP</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Patent ductus arteriosus</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Coarctation of the aorta</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Necrotising enterocolitis neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Endocarditis staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Meningitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Neurological infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Nocosomial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Septic embolus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Intraventricular haemorrhage neonatal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Necrotising enterocolitis neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Apnoea neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pulmonary interstitial emphysema syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="72"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia neonatal</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="70"/>
                <counts group_id="E2" events="37" subjects_affected="31" subjects_at_risk="72"/>
                <counts group_id="E3" events="52" subjects_affected="31" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Coagulation disorder neonatal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Patent ductus arteriosus</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="70"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="72"/>
                <counts group_id="E3" events="26" subjects_affected="24" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Necrotising enterocolitis neonatal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Regurgitation</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="70"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="70"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Sepsis neonatal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" events="31" subjects_affected="22" subjects_at_risk="70"/>
                <counts group_id="E2" events="35" subjects_affected="25" subjects_at_risk="72"/>
                <counts group_id="E3" events="22" subjects_affected="15" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Feeding intolerance</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="72"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypermagnesaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Agitation neonatal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Bradycardia neonatal</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage neonatal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E3" events="15" subjects_affected="12" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Jaundice neonatal</sub_title>
                <counts group_id="E1" events="47" subjects_affected="41" subjects_at_risk="70"/>
                <counts group_id="E2" events="50" subjects_affected="49" subjects_at_risk="72"/>
                <counts group_id="E3" events="46" subjects_affected="41" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="70"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="72"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Retinopathy of prematurity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Weight decrease neonatal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Apnoea neonatal</sub_title>
                <counts group_id="E1" events="39" subjects_affected="31" subjects_at_risk="70"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="72"/>
                <counts group_id="E3" events="31" subjects_affected="27" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Atelectasis neonatal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Bronchopulmonaria dysplasia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Nasal inflammation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Neonatal tachypnoea</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="70"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="72"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Steering Committee is responsible for publications, including who will be authoring publications. The sponsor has the right to review publications before they are published and can provide suggested edits, but cannot require changes or prevent publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Clogging of a in-line filter led to a higher number of treatment interruptions than expected. This primarily affected one batch of supplies that were, by chance, predominantly used in European sites.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Executive Director of Biostatistics &amp; Data Management</name_or_title>
      <organization>Windtree Therapeutics, Inc.</organization>
      <phone>215-488-9477</phone>
      <email>psimmons@windtreetx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

